Giles Scuderi, MD
Orthopaedic Surgery · New York, NYNPI 1639113863
Payments from drug & device makers
Across 357 payments — averaging $30,448 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$10.6M
- Next Science LLC$106K
- KCI USA, Inc.$81K
- Solventum Corporation$72K
- Convatec Inc.$7K
- Canary Medical USA LLC$2K
- plus $738 from 4 others
What the payments were for
- Royalty or licence$10,186,35396%
- Consulting fees$318,0023%
- Speaking & faculty fees$35,0380%
- Travel & lodging$16,2940%
- Food & beverage$10,4830%
- Education$88,5761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 311 | $10,600,668 |
| Next Science LLC | 10 | $106,046 |
| KCI USA, Inc. | 18 | $80,990 |
| Solventum Corporation | 7 | $72,318 |
| Convatec Inc. | 2 | $7,425 |
| Canary Medical USA LLC | 2 | $1,675 |
| Smith+Nephew | 3 | $308 |
| Pacira Therapeutics, Inc. | 2 | $247 |
| Stryker | 1 | $169 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona$10,256,805
- Persona Revision$295,456
- PREVENA$36,890
- Avenir$36,705
- G7$34,732
- Arcos$34,732
- Trabecular Metal Shapes-Knees$9,282
- Regenerex-Knees$9,282
- V.A.C. VERAFLO$8,850
- SpotOn$8,050
- PREVENA RESTOR ARTHROFORM$7,700
- ACTIV.A.C.$7,350
- PROMOGRAN PRISMA$6,650
- Bair Hugger$6,300
- V.A.C. DERMATAC$6,300
- 3M Ioban$6,300
- 3M DuraPrep Surgical$5,600
- PREVENA RESTOR BELLAFORM$4,800
- 3M SoluPrep$4,800
- AQUACEL AG$4,400
How this compares
$10,869,860 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 160 | $7,358 |
| Celecoxib | 141 | $2,484 |
| Meloxicam | 270 | $597 |
| Naproxen | 55 | $439 |
| Ibuprofen | 49 | $408 |
| Amoxicillin | 110 | $383 |
| Cyclobenzaprine Hcl | 35 | $336 |
| Oxycodone Hcl | 43 | $190 |
| Methylprednisolone | 11 | $105 |
| Clindamycin Hcl | 17 | $52 |
| Pantoprazole Sodium | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in New York
- Anthony RomeoNew York$27M
- Lawrence LenkeNew York$26.8M
- Edwin SuNew York$14.1M
- William RicciNew York$11.6M
- Steven HaasNew York$11.5M
- Joseph ZuckermanNew York$9.9M
- Evan FlatowNew York$9.6M
- Bradford ParsonsNew York$9.4M
- Geoffrey WestrichNew York$8M
- Andrew PearleNew York$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.